Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease

Konstantinos Papamichael, Ravy K. Vajravelu, Byron P. Vaughn, Mark T. Osterman, Adam S. Cheifetz

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Fingerprint

Dive into the research topics of 'Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Medicine & Life Sciences